baber/WOPTO huggingface dataset:
Patent NZ-540111-A (NZ)
Title: Synergistic fungicidal compositions
Inventor: OWEN WILLIAM JOHN
IPC: A01N47/22
Filed: 2003-12-05
Abstract: Disclosed is a synergistic fungicidal composition comprising a first composition represented by formula III or formula IIIa, and a second composition selected from a), b), c), d), or e) below, wherein: a) is a compound of formula II, b) is chlorothalonil, copperhydroxide, copper oxychloride, folpet, captan, fluazinam, cyazofamid, ethaboxam, cymoxanil, dimethomorph, iprovalicarb, benthivalicarb, fosetyl-Al/phosphonic acid, propamocarb, an epimeric and diastereoisomeric form of dipeptide fungicide, or a N-sulfonylvaline amide, or a combination thereof; c) is a mitochondrial Qo-site inhibitor selected from the group: azoxystrobin, picoxystrobin, trifloxystrobin, pyraclostrobin, kresoximmethyl, metominostrobin, fluoxastrobin, enestroburin, fenamidone and famoxadone, or a combination thereof; d) is an acylalanine; and e) is an alkylenebis(dithiocarbamate).
Patent NZ-541659-A (NZ)
Title: Pharmaceutical composition comprising with a pH between 4 and 9 to treat SLE comprising an aqueous carrier, a pharmaceutically acceptable salt of a peptide and a substituted beta-cyclodextrin
Inventor: COHEN-VERED SHARON
IPC: A61K39/00
Filed: 2004-01-14
Abstract: The subject invention provides a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formula NH2-Gly Tyr Tyr Tip Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-CoOH; and a substituted b-cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition has a pH between 4 and 9, the use of said pharmaceutically acceptable salt of a peptide in the manufacture of a medicament for alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject and a process for preparation of said medicament.
Patent NZ-542334-A (NZ)
Title: Method of construction
Inventor: LUCAS CHRISTOPHER FRANCIS
Filed: 2005-11-07
Abstract: A method of creating a support structure which incorporates a supporting platform and at least one integral support leg using a blow moulding technique, including the steps of: a) defining the optimum thickness of material required for the support leg(s) for strength purposes; b) defining the optimum height for the support legs; c) determining the volume of the parison, to be introduced across the leg part of the mould; d) designing the mould leg interior to ensure that for the given parison volume the thickness of material subsequently blow moulded around the surface area of the support leg is sufficient to provide the required strength; and e) blow moulding material into the mould as designed by steps a) to d). Typically, the support structure is a pallet.
Patent NZ-543774-A (NZ)
Title: Combinations of (Z)-3-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone
Inventor: HILBERG FRANK
IPC: A61K31/56
Filed: 2004-04-24
Abstract: Disclosed is a pharmaceutical combination comprising effective amounts of: (i) (Z)-3-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof (such as the monoethanesulfonate salt); and (ii) at least a further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent selected from the group consisting of the steroids dexamethasone or prednisone, the dual EGFR/HER2 antagonist 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}7-((S)-tetrahydrofuran-3-yloxy)-quinazoline or a pharmaceutically acceptable salt (such as the di-maleic acid salt), tautomer, or stereoisomer thereof, the platinum compound carboplatin, or the anti-cancer drugs from plants paclitaxel or docetaxel; and optionally adapted for a co-treatment with radiotherapy or radio-immunotherapy, in the form of a combined preparation adapted for simultaneous, separate or sequential administration. Also disclosed is the use of the above pharmaceutical combination for the manufacture of a medicament, optionally adapted for a co-treatment with radiotherapy or radio-immunotherapy, for the treatment of a disease involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis (including diseases such as a solid tumour, urogenital cancer, lung cancer, gastrointestinal cancer, head and neck cancer, malignant mesothelioma, breast cancer, malignant melanoma, or bone and soft tissue sarcomas, haematologic neoplasias, malignant human neoplasias, refractory or relapsed multiple myeloma, acute or chronic myelogenous leukaemia, myelodysplastic syndrome, or acute lymphoblastic leukaemia and non-oncological diseases (such as diabetic retinopathy, rheumatoid arthritis, or psoriasis)), in a human or non-human mammalian body.
Patent NZ-546517-A (NZ)
Title: Fungicidal agrochemical compositions containing a copper salt and polylysine
Inventor: PFEIFFER THOMAS
IPC: A01N59/20
Filed: 2004-10-15
Abstract: Disclosed are fungicidal agrochemical compositions containing (a) at least one copper salt, and (b) polylysine, and/or (c) at least one polylysine derivative, the use of polylysine, polylysine derivatives, or a combination of polylysine and polylysine derivatives in copper-containing fungicidal formulations for controlling phytopathogenic fungi. Also disclosed is a method for controlling phytopathogenic fungi, which comprises applying an agrochemical composition to the pest in question or to the materials, plants, soil and seeds to be protected from the harmful organism in question.
Patent NZ-547224-A (NZ)
Title: Beta-amyloid-analogue-T-cell epitope vaccine
Inventor: RASMUSSEN PETER BIRK
IPC: A61K39/385
Filed: 2002-08-20
Abstract: Disclosed is the use of an immunogen, which a) is a polyamino acid that consists of at least one copy of a subsequence of residues 672-714 in SEQ ID NO: 2, wherein at least one foreign T-helper epitope (TH epitope) is incorporated by means of amino acid addition and/or insertion and/or deletion and/or substitution; or b) is a conjugate comprising a polyhydroxypolymer backbone to which is separately coupled a polyamino acid as defined in a); or c) is a nucleic acid that encodes the polyamino acid as defined in a); or d) is a non-pathogenic microorganism or virus which is carrying a nucleic acid fragment which encodes and expresses the polyamino acid as defined in a), in the preparation of a pharmaceutical preparation containing the immunogen for the treatment, prevention or amelioration in an animal of Alzheimer's disease or other diseases characterized by amyloid deposition. Also disclosed is a polyamino acid or conjugate, a nucleic acid fragment which encodes this polyamino acid, and a transformed cell carrying the nucleic acid fragment as described above.
Patent NZ-553416-A (NZ)
Title: Barb configurations for barbed sutures
Inventor: LEUNG JEFFERY C
IPC: A61B17/08
Filed: 2003-09-29
Abstract: A barbed suture for connecting human or animal tissue, the suture comprising (a) an elongated body having a first end, a second end and a diameter and (b) a plurality of barbs projecting from the body, each barb facing in a direction and being adapted for resisting movement of the suture, when in tissue, in an opposite direction from the direction in which the barb faces, wherein the barbs have a configuration comprising varying barb sizes.
Patent NZ-554842-A (NZ)
Title: Irrigation monitor that monitors an irrigator to ensure it is operating correctly while its water pump is operating
Inventor: FINNIE PHILLIP JAMES
IPC: A01G25/16
Filed: 2007-11-01
Abstract: An irrigation monitor for use with a K-Line type irrigator or for incorporation into a new K-Line type irrigator is disclosed. The irrigation monitor includes a pressure sensor, a transmitter, a receiver means and a mechanical or electronic control system. In use the pressure sensor is associated with the K-Line type irrigator to sense pressure. The pressure information is interrogated by the control system via the transmitter and receiver to establish if there is pressure or not to thereby decide whether a pump should or should not be supplying water or effluent to the irrigator.
Patent NZ-555926-A (NZ)
Title: Determination of neutrophil gelatinase-associated lipocalin (NGAL) as a diagnostic marker for renal disorders
Inventor: UTTENTHAL LARS OTTO
Filed: 2005-12-20
Abstract: Disclosed is a method of testing for the likelihood of a renal disorder in a human being, wherein said method discriminates between a renal disorder and a condition that is not affecting the kidney, said methods comprising the steps of: (i) determining the concentration of human neutrophil gelatinase-associated lipocalin (NGAL) in a sample of bodily fluid from the human being, (ii) comparing said concentration with a predetermined cutoff value, said cutoff value being 250 ng/ml or a higher value chosen to exclude lower concentrations of NGAL associated with conditions that are not affecting the kidney, wherein a concentration above the cutoff value is indicative of a renal disorder.
Patent NZ-555945-A (NZ)
Title: Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
Inventor: OLD DAVID W
IPC: A61K31/192
Filed: 2006-01-10
Abstract: Provided is a compound comprising the formula depicted below or a pharmaceutically acceptable salt thereof or an ester prodrug thereof; wherein Y is an organic acid functional group or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group; A is -(CH2)6-, cis -CH2CH=CH-(CH2)3-, or -CH2Ca"C-(CH2)3-, wherein 1 or 2 carbon atoms may be substituted with S or O; or A is -(CH2)m-Ar-(CH2)o- wherein Ar is interphenylene, interthienylene, interfurylene or interpyridinylene, the sum of m and o is from 1 to 4, and wherein one CH2 may be substituted with S or O; B is C=O, CH2, CHOH, CHCI, CHF, CHBr, or CHCN; G is OH or H; and D is aryl or heteroaryl which may be substituted with a substituents having up to 12 non-hydrogen atoms each and as many hydrogen atoms as necessary. The compounds can be used to treat glaucoma or ocular hypertension.
Patent NZ-563441-A (NZ)
Title: Appliance for producing hot drinks
Inventor: MORGANDI ARTURO
IPC: A47J31/56
Filed: 2006-05-17
Abstract: An appliance (1) for producing hot drinks comprising a water heating device (30) is disclosed. The appliance includes a heating source (32); a seat (50) adapted to receive a product for preparing the drink; a duct (40) for feeding hot water from the water heating device to the seat (50); and a control device (60) operatively associated with heating source for adjusting the temperature of water contained in the water heating device (30). The appliance further comprises a compensating device (400) to dynamically compensate for temperature drop undergone by the water flowing along the duct (40) from the water heating device (30) to the seat (50). The compensating device (400) detects a quantity indicative of the temperature drop undergone by the water flowing along the duct. The control device (60) is operatively connected to the compensating device (400) so as to dynamically adjust the temperature of the water contained in the water heating device (30) based on the quantity detected by the compensating device (400).
Patent NZ-569144-A (NZ)
Title: Pharmaceutical antibody compositions with resistance to soluble CEA - comprising IgG1antibodies that bind to CEA
Inventor: RAU DORIS
IPC: C12N15/13
Filed: 2006-12-21
Abstract: Disclosed is an IgG1 antibody that specifically binds to human CEA. The antibody is adapted for the treatment of progressive tumours, late stage tumours, tumour patients with high tumour load/burden, metastatic tumours or tumour patients with a CEA serum concentration higher than 100ng/ml. Also disclosed are processes for producing the antibody, pharmaceutical compositions comprising the antibody and the use of the antibody in the manufacture of a medicament to treat epithelial tumours selected from gastrointestinal adenocarcinoma, breast adenocarcinoma and lung adenocarcinoma.
Patent NZ-571309-A (NZ)
Title: Pyrido[2,3-B]pyrazine and [1,8]-naphthyridine derivatives as ALK and c-Met inhibitors
Inventor: MILKIEWICZ KAREN L
IPC: C07D471/04
Filed: 2007-05-01
Abstract: Disclosed are Pyrido [2, 3-B] pyrazine and [1, 8] -naphthyridine derivatives represented by formula (I), or pharmaceutically acceptable salts thereof. Also disclosed is the use of the said compounds for treating ALK or c-Met mediated disorders or conditions.
Patent NZ-572401-A (NZ)
Title: N1,n4-bis(buta-1,3-dienyl)butane-1,4-diamine pharmaceutical compositions and uses thereof
Inventor: BASU HIRAK S
IPC: A61P13/08
Filed: 2007-05-03
Abstract: Disclosed is the use of N,N'-bis(2,3-butadienyl)-1,4-butanediamine or a pharmaceutically suitable salt or solvate thereof as a monotherapy for treating cancer of the prostate in a human male and male dog.
Patent NZ-578871-A (NZ)
Title: Crystalline forms of an 8-azabicyclo[3.2.1]octane compound useful as mu opiod receptor antagonists
Inventor: DALZIEL SEAN
IPC: C07D451/02
Filed: 2008-02-27
Abstract: Disclosed is a crystalline salt form which is the sulfate salt of 3-endo-(8-{ 2- [cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl} -8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. Also disclosed is a process for preparing a crystalline sulfate salt of 3-endo-(8-{ 2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl} -8-aza-bicyclo[3.2.1]oct-3-yl)benzamide. Also disclosed is the bisulfite adduct of N-cyclohexylmethyl-(2-oxoethyl)-carbamic acid benzyl ester. Also disclosed is the use of the crystalline salt for the manufacture of a medicament for the treatment of a disease or medical condition in a mammal ameliorated by treatment with a mu opioid receptor antagonist, wherein the disease or condition is opioid-induced bowel dysfunction or post-operative ileus.
Patent NZ-582310-A (NZ)
Title: New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
Inventor: PEGLION JEAN-LOUIS
IPC: C07C209/46
Filed: 2009-12-23
Abstract: Disclosed is the process for the synthesis of a compound of formula (VI) in racemic or optically active form wherein A represents H2C-CH2 or HC=CH, characterised that the compound of formula (VII) in racemic or optically active form is subjected to a reductive amination reaction with a compound of formula (VIII) in the presence of a reducing agent, such as sodium triacetoxyborohydride, in an organic solvent or a mixture of organic solvents, such as tetrahydrofuran and dichloromethane.
Patent NZ-588033-A (NZ)
Title: Methods of treating a mif-mediated disorder
Inventor: BERNHAGEN JURGEN
IPC: A61K31/64
Filed: 2009-03-20
Abstract: Disclosed is a peptide that inhibits MIF binding to CXCR2 and CXCR4, wherein the peptide specifically binds to or competes with an N-Loop motif of MIF. Also disclosed is the use of a peptide for the manufacture of a medicament for the treatment of an inflammatory disorder.
Patent NZ-589207-A (NZ)
Title: Shield for hand held air blowing lance
Inventor: MORGAN STUART
IPC: B05B1/00
Filed: 2009-04-21
Abstract: 589207 A nozzle and shield assembly (10) supported by a hand held lance (50) is disclosed. The nozzle assembly has an end cap (40) and a nozzle (30) and a shield (21) is attachable to the nozzle assembly so the nozzle (30) is protected from damage. The shield is larger at a first end closer to the lance (50) than at the opposing end. The arrangement is such that air can flow into the space (23) between the shield (21) and lance (50) and be accelerated due to venturi effect from air exiting the nozzle (30).
Patent NZ-589396-A (NZ)
Title: Fungicidal compositions comprising a dihalomethylidene-benzonorbornene derivative and fludioxonil
Inventor: TOBLER HANS
IPC: A01N43/56
Filed: 2008-04-23
Abstract: Disclosed are compositions comprising fludioxonil and a dihalomethylidene-benzonorbornene derivative, represented by the general formula (I) wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo. Also disclosed is a method of controlling diseases on useful plants or on propagation material thereof caused by phytopathogens, comprising applying the said composition to the plants. (62) Divided Out of 580186
Patent NZ-592209-A (NZ)
Title: Method for for multilingual information retrieval
Inventor: MOULINIER ISABELLE
IPC: G06F17/30
Filed: 2006-01-04
Abstract: A computer-implemented method for retrieving multi-lingual information in a server interacting with a collection of documents and a set of language-specific indices is disclosed. In at least one data-storage device a set of one or more language-specific indices are defined for a collection of documents with each index including stemmed and non-stemmed versions of terms contained in the documents; A query is received from a user, with the query associated with a set of one or more target languages. Using at least one processor the query is parsed into one or more terms with each term associated with a corresponding language identifier and a stemmed version of the term. Using at least one processor the non-stemmed and stemmed versions of each term are translated into each of the target languages to define respective sets of one or more equivalent query terms. Using at least one processor a set of documents are identified from the collection of documents for each of the target languages, with each set identified based on the equivalent query term for the corresponding target language.
Patent NZ-592334-A (NZ)
Title: Cushion with multiple zones of foam having differing resistance to resilient deformation
Inventor: MCCLUNG MARK D
IPC: A47C17/00
Filed: 2009-11-19
Abstract: Disclosed is a cushion assembly defining a thickness direction comprises at least one covering layer (18a, 18b) and a core layer (16). The core layer comprises a first member (40) and a second member (42). The covering layer spans continuously across both the first and second members in a direction generally transverse to the thickness direction, and the first member is disposed adjacent a forward area of the cushion assembly. The second member is disposed adjacent a back surface of the first member. The second member has a higher resistance to resilient deformation than the first member, and the first member has a higher resistance to resilient deformation than the at least one covering layer. The core layer further has a third member (44) positioned rearward of the second member. The width of the third member is such that a back cushion (12) of a furniture member (10) substantially covers the third member. The first member has a higher resistance to resilient deformation that the third layer.
Patent NZ-592942-A (NZ)
Title: Method for cyclically operating coke oven banks from “heat recovery” coke oven chambers
Inventor: KIM RONALD
IPC: C10B15/02
Filed: 2009-12-18
Abstract: 592942 Disclosed is a method for cyclical operation of a sequence of an even or odd number of at least four coke oven banks (1). The coke oven banks (1) include a sequence of at least four coke oven chambers (I-X) of the “Heat Recovery” type. The coke oven banks (1) are linked to a boiler system (2) in which the heat of hot waste gases from coke oven banks (1) is utilized to generate steam. The coke oven chambers (I-X) are pushed and charged within exactly determined time intervals from a frontal side with a coke pusher machine (11) into the opposite direction of a coke oven chamber, and directly after pushing a renewed charging of the individual coke oven chambers and a renewed coking cycle are accomplished. A first pushing cycle in which a first coke oven chamber of a first coke oven bank is initially pushed and charged, and then in successive order, a first coke oven chamber of every second coke oven bank is consecutively pushed and charged until a first coke oven chamber of the last coke oven bank in this sequence has been pushed and charged. A second pushing cycle in which a first coke oven chamber of a second coke oven bank is initially pushed and charged, and then in successive order a first coke oven chamber of every second coke oven bank is pushed and charged until a first coke oven chamber of the last coke oven bank in this sequence has been pushed and charged. A third pushing cycle in which a second coke oven chamber of the first coke oven bank is pushed and charged, and then in successive order a second coke oven chamber of every second coke oven bank is pushed and charged until a second coke oven chamber of the last coke oven bank in this sequence has been pushed and charged. A fourth pushing cycle in which a second coke oven chamber of the second coke oven bank is pushed and charged, and then in successive order a second coke oven chamber of every second coke oven bank is pushed and charged until the second coke oven chamber of the last coke oven bank in this sequence has been pushed and charged. Over the temporal mean of all coking cycles a very even production of waste heat can be passed in this manner into the boiler facilities so that the boilers (A-E) can be supplied very evenly with waste heat.
Patent NZ-595775-A (NZ)
Title: Fused imidazole derivatives as trpv3 antagonist
Inventor: LINGAM V
IPC: C07D235/02
Filed: 2009-12-23
Abstract: Disclosed herein are fused imidazole compounds of formula (I), wherein the substituents are as defined within the specification; processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful the their Transient Receptor Potential Vanilloid 3 (TRPV3) activity and as such are useful in the treatement of pain, acute pain, chronic pain, nociceptive pain, neuropathic pain, post-operative pain, dental pain, cancer pain, cardiac pain arising from an ischemic myocardium, pain due to migraine, arthralgia, neuropathies, neuralgia, trigeminal neuralgia nerve injury, diabetic neuropathy, neurodegeneration, retinopathy, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, urinary incontinence, vulvodynia, gastrointestinal disorders such as irritable bowel syndrome, gastro-esophageal reflux disease, enteritis, ileitis, stomach-duodenal ulcer, inflammatory bowel disease, Crohn's disease, celiac disease, an inflammatory disease such as pancreatitis, a respiratory disorder such as allergic and non-allergic rhinitis, asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, dermatitis, pruritic conditions such as uremic pruritus, fervescence, muscle spasms, emesis, dyskinesias, depression, Huntington's disease, memory deficits, restricted brain function, amyotrophic lateral sclerosis (ALS), dementia, arthritis, osteoarthritis, diabetes, obesity, urticaria, actinic keratosis, keratocanthoma, alopecia, Meniere's disease, tinnitus, hyperacusis, anxiety disorders and benign prostate hyperplasia. Examples of particularly preferred compounds include: 6-{ 2-[(E)-2-(2-Butoxy-3-methoxyphenyl)vinyl]-3H-imidazo[4,5-b]pyridin-3-yl} nicotinonitrile; 6-{ 2-[(E)-2-(2-Pentyloxy-3-methoxyphenyl)vinyl]-3H-imidazo[4,5-b]pyridin-3-yl} nicotinonitrile; Methyl 6-{ 2-[(E)-2-(2-Cyclopentyloxy-3-methoxyphenyl)vinyl]-6-fluoro-1H-benzimidazol-1-yl} nicotinate; 6-{ 2-[(E)-2-(2-[Cyclopentyloxy]-3-methoxyphenyl)vinyl]-1H-imidazo[4,5-c]pyridin-1-yl} nicotinonitrile 6-(2-{ (E)-2-[2-(Cyclopentyloxy)-3-difluoromethoxyphenyl]vinyl} -3H-imidazo[4,5-b]pyridin-3-yl)nicotinonitrile.